LEADER 01644oam  2200481   450 
001 9910706954803321
005 20210316154901.0
035   $a(CKB)5470000002459929
035   $a(OCoLC)852783298
035   $a(EXLCZ)995470000002459929
100   $a20130713d2000      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aCounterfeit bulk drugs $ehearings before the Subcommittee on Oversight and Investigations of the Committee on Commerce, House of Representatives, One Hundred Sixth Congress, second session, June 8 and October 3, 2000
210  1$aWashington :$cU.S. Government Printing Office,$d2000.
215   $a1 online resource (iii, 423 pages) $cillustrations
300   $a"Serial no. 106-164."
517   $aCounterfeit bulk drugs 
606   $aDrugs$xInspection$zUnited States
606   $aDrugs$xStandards$zUnited States
606   $aDrug adulteration$xGovernment policy$zUnited States
606   $aPharmaceutical industry$zUnited States$xQuality control
606   $aProduct counterfeiting$zUnited States
615  0$aDrugs$xInspection
615  0$aDrugs$xStandards
615  0$aDrug adulteration$xGovernment policy
615  0$aPharmaceutical industry$xQuality control.
615  0$aProduct counterfeiting
801  0$bOCLCE
801  1$bOCLCE
801  2$bOCLCO
801  2$bOCLCQ
801  2$bOCLCF
801  2$bOCLCO
801  2$bOCLCQ
801  2$bGPO
906   $aBOOK
912   $a9910706954803321
996   $aCounterfeit bulk drugs$93436007
997   $aUNINA